HIFU is a state-of-the-art treatment that utilizes high-frequency sound waves to target and destroy prostate cancer cells
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
The aim is to create new genomics solutions that could combat cancer and advance market access
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Subscribe To Our Newsletter & Stay Updated
